調査報告

国立研究開発法人日本医療研究開発機構（AMED）主催「プロジェクト連携シンポジウム」より ― アカデミア発シーズ開発のシナジー効果促進のために*

福島　雅典　　中谷　英仁　　尾前　　薫
木村　泰子　　小島　伸介　　周　　玢
公益財団法人 先端医療振興財団 臨床研究情報センター

Academic-origin disruptive innovation and its management ― Report from the "Consolidated Strategic Management Meeting" convened by the Japan Agency for Medical Research and Development (AMED)

Masanori Fukushima　Eiji Nakatani　Kaoru Omae
Yasuko Kimura　Shinsuke Kojima　Bin Zhou
Translational Research Informatics Center, Foundation for Biomedical Research and Innovation

Abstract

The Japan Agency for Medical Research and Development (AMED) has convened eight "Consolidated Strategic Management Meetings" from November 2015 through February 2016, depending on its main disease-oriented projects it focuses on. The aim of these Meetings is to share the information and maximize the synergy effect of the disruptive innovations developed from every ARO (academic research organization) in "Project for Translational and Clinical Research Core Centers", with other projects within AMED as successful experience, as well as to evaluate every innovation's international competitive edge.

As a supporting organization for "Project for Translational and Clinical Research Core Centers", we have surveyed and reported the status of competing products, for the purpose of strengthening the project management. In the development of drugs and medical devices, it is required to comprehensively evaluate the following: 1. Strength of the patent itself, 2. Adequacy of the POC (proof of concept) of the animal model, 3. Priority of business and market, 4. Existing treatment, and 5. Competing products. Particularly, the status of the development of competing products changes from moment to moment, thus, we should keep in mind that its monitoring is mandatory for the project management. Here, we have summarized six surveys out of eight "Consolidated Strategic Management Meetings".

Key words

disruptive innovation, regenerative medicine, check-point inhibitor, brain-machine interface, Alzheimer's disease

Rinsho Hyoka（*Clinical Evaluation*）. 2016；44：429-52.

＊ 本稿は，2015年11月6日～2016年2月9日に8回にわたり開催された国立研究開発法人日本医療研究開発機構　革新的医療技術創出拠点プロジェクト　平成27年度プロジェクト連携シンポジウム（統合戦略会議）における調査報告の内，6回分を論文化したものである．